AdaptHealth Reports Significant Net Loss and $128M Goodwill Impairment in 2025 Annual Report

summarizeSummary

AdaptHealth Corp. reported a net loss of $70.8 million for 2025, a significant decline from the prior year's net income, driven by a $128.0 million goodwill impairment charge in its Diabetes Health segment and a slight overall revenue decrease.

check_boxKey Events

• Financial Performance Decline

  The company swung to a net loss of $70.8 million in 2025, a significant decrease from the $90.4 million net income reported in 2024. This follows the 8-K filing on the same day reporting the Q4 and full-year 2025 results.

• Goodwill Impairment

  AdaptHealth recognized a $128.0 million non-cash goodwill impairment charge in its Diabetes Health reporting unit for the year ended December 31, 2025, driven by revised financial projections. Additionally, the Wellness at Home and Respiratory Health segments have fair values less than 10% and 20% of their carrying values, respectively, indicating potential future impairment.

• Revenue Trends

  Total net revenue decreased by 0.5% to $3.24 billion in 2025 compared to $3.26 billion in 2024. This was primarily due to dispositions in the Wellness at Home segment, which reduced net revenue by $92.4 million, partially offset by a 1.7% increase in organic revenue.

• Legal Settlements & Investigations

  The company agreed to settle a securities class action for $35.0 million ($1.0 million from the company, $34.0 million from insurers) and a North Carolina class action for $14.5 million. Two civil investigative demands from the U.S. Attorney's Office regarding alleged false claims are ongoing, with potential material adverse effects yet to be determined.

auto_awesomeAnalysis

The 2025 annual report reveals a challenging year for AdaptHealth, marked by a substantial swing to a net loss and a significant goodwill impairment, particularly impacting the Diabetes Health segment. While the company achieved modest organic revenue growth, this was offset by strategic dispositions and overall revenue contraction. The ongoing legal investigations and the looming impact of new healthcare legislation (OBBBA and CMS Competitive Bidding Program) introduce considerable uncertainty regarding future reimbursement and operational costs. Investors should monitor the resolution of these legal and regulatory challenges, as they pose material risks to the company's financial stability and future profitability. The successful remediation of the internal control weakness is a positive step for governance but is overshadowed by the broader financial and operational pressures.